首页> 美国卫生研究院文献>Scientific Reports >8u a pro-apoptosis/cell cycle arrest compound suppresses invasion and metastasis through HSP90α downregulating and PI3K/Akt inactivation in hepatocellular carcinoma cells
【2h】

8u a pro-apoptosis/cell cycle arrest compound suppresses invasion and metastasis through HSP90α downregulating and PI3K/Akt inactivation in hepatocellular carcinoma cells

机译:促凋亡/细胞周期阻滞化合物8u通过抑制HSP90α的下调和PI3K / Akt失活抑制肝癌细胞的侵袭和转移

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

8u, an acridine derivative, has been proved effective anti-hepatocarcinoma effect, while the underlying mechanism remains unclear. Here, metabolomics and proteomics approaches were applied to study its anti-cancer mechanism and explore its effect on HepG2 cells’ invasion and metastasis abilities. The results showed that 8u significantly suppressed HepG2 cells migration and enhanced cell-to-cell junctions. The inhibition effect of 8u on invasion and metastasis disappeared after HSP90α gene silencing, and was reversed after HSP90α overexpression. The biological experimental results indicated that 8u also blocked PI3K/Akt pathway, thereby reducing fatty acid synthase (FASN) protein expression and disordering intracellular lipid metabolism to inhibit cell invasion and metastasis. In addition, HSP90α protein and PI3K/Akt pathway could co-adjust to each other. These findings demonstrated that 8u could efficiently suppress the invasion and metastasis of HepG2 cells by decreasing the expression of HSP90α protein and inhibiting the PI3K/Akt signaling pathway, which could be used as a potential candidate for the treatment of HCC.
机译:u啶衍生物8u已被证明具有有效的抗肝癌作用,但其潜在机制尚不清楚。在这里,使用代谢组学和蛋白质组学方法研究其抗癌机制,并探讨其对HepG2细胞侵袭和转移能力的影响。结果显示8u显着抑制了HepG2细胞迁移并增强了细胞间连接。 HSP90α基因沉默后,8u对侵袭和转移的抑制作用消失,而在HSP90α过表达后则逆转。生物学实验结果表明8u还阻断了PI3K / Akt通路,从而降低了脂肪酸合酶(FASN)的蛋白表达并扰乱了细胞内脂质代谢,从而抑制了细胞的侵袭和转移。此外,HSP90α蛋白和PI3K / Akt途径可以相互调节。这些发现表明8u可以通过降低HSP90α蛋白的表达并抑制PI3K / Akt信号通路来有效抑制HepG2细胞的侵袭和转移,可作为治疗HCC的潜在候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号